Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 473 - Heterocyclic compounds containing purine ring systems
Patents for C07D 473 - Heterocyclic compounds containing purine ring systems (11,932)
01/2011
01/05/2011CN101939321A Production method and production device for composition having high content of theobromine
01/05/2011CN101939054A Organic compounds
01/05/2011CN101215287B Method for synthesizing guanine from urea
01/04/2011CA2415275C Improved methods of synthesis for 9-substituted hypoxanthine derivatives
12/2010
12/30/2010US20100331329 Benzamide derivatives useful as histone deacetylase inhibitors
12/30/2010US20100331306 Heterocyclic compounds and their uses
12/30/2010US20100331302 N-(2-(hetaryl)aryl) arylsulfonamides and n-(2-(hetaryl)hetaryl arylsulfonamides
12/30/2010US20100331297 Modulation of protein trafficking
12/29/2010WO2010151735A2 Heterocyclic compounds and their uses
12/29/2010WO2010149541A1 Novel oxazolone and pyrrolidinone-substituted arylamides
12/29/2010WO2010149326A1 Acid-labile trigger units
12/29/2010EP2266964A1 Acid-labile trigger units
12/29/2010EP2265626A2 Nucleotide analogues with quaternary carbon stereogenic centers and methods of use
12/29/2010EP2265612A1 Substituted xanthine derivatives
12/29/2010EP2265334A2 Substituted xanthine derivatives
12/29/2010EP1438052B1 Quinazolin-4-ones as inhibitors of human phosphatidylinositol 3-kinase delta
12/29/2010CN1968691B Composition for acceleration of alcohol metabolism or recuperation from fatigue through gluconeogenesis
12/29/2010CN101928288A Small molecule compositions for binding to HSP90
12/29/2010CA2766320A1 Acid-labile trigger units
12/29/2010CA2765819A1 Heterocyclic compounds and their uses as inhibitors of p13 k activity
12/29/2010CA2765817A1 Heterocyclic compounds and their uses
12/29/2010CA2754654A1 Novel oxazolone and pyrrolidinone-substituted arylamides
12/23/2010US20100324159 Novel ion exchange porous resins for solid phase extraction and chromatography
12/23/2010US20100324062 Compounds and compositions as protein kinase inhibitors
12/23/2010US20100324047 Raf kinase modulators and methods of use
12/23/2010US20100324043 Bicyclic And Tricyclic Compounds As KAT II Inhibitors
12/23/2010US20100324040 9-(pyrazol-3-yl)-9h-purine-2-amine and 3-(pyrazol-3-yl) -3h-imidazo[4,5-b] pyridin-5- amine derivatives and their use for the treatment of cancer
12/22/2010EP2264028A1 Pyrazole compounds useful as protein kinase inhibitors
12/22/2010CN101925602A Crystalline form of abacavir that is essentially free of solvent
12/21/2010CA2444130C Adenine derivatives
12/21/2010CA2214406C Use of penciclovir for the treatment of human herpes-virus-8
12/16/2010WO2010142761A1 The succinate of tenofovir disoproxil
12/16/2010US20100317671 Xanthine-based cyclic gmp-enhancing rho-kinase inhibitor inhibits physiological activities of lung epithelial cell line
12/16/2010US20100316607 Hepatitis c virus inhibitors
12/15/2010EP2260850A2 A2A receptor antogonists for use in the treatment of movement disorders
12/15/2010EP2260038A1 Purine derivatives as a3 receptor- selective agonists
12/15/2010EP1411954B1 Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
12/15/2010CN1984660B 4-arylamino-quinazolines as activators of aspartic acid specificity cysteine protease and inducers of apoptosis
12/15/2010CN101918000A Use of purine derivatives for the manufacture of a medicament
12/15/2010CN101914097A Technological method for extracting caffeine and tea polyphenol mixture from tea step by step
12/15/2010CN101497615B Substituted purine, preparation and use in medicine
12/14/2010US7851615 Lipophilic conjugated iRNA agents
12/14/2010CA2591566C Process for the preparation of an aminoalcohol
12/14/2010CA2485641C Novel condensed imidazole derivatives
12/14/2010CA2433858C Purine derivatives as purinergic receptor antagonists
12/09/2010WO2010139289A1 Substituted 6-(2-hydroxybenzylamino)purine derivatives, their use as medicaments and compositions containing these derivatives
12/09/2010US20100311768 Use of purine derivatives for the manufacture of a medicament
12/09/2010US20100311721 Compounds
12/09/2010US20100311175 Mass tags for quantitative analyses
12/08/2010EP2258689A1 Benzylated PDE4 inhibitors
12/08/2010CN101906106A Novel heterocyclic compounds as HSP90-inhibitors
12/08/2010CN101544641B Novel anticancer-active purine nucleoside compounds modified by monoazacrown ether at 6-position and preparation method thereof
12/08/2010CN101195619B Novel method for fine purification of theobromine
12/07/2010US7846937 such as 1-amino-cyclopropanecarboxylic acid 2-(2-amino-6-oxo-1,6-dihydro-purin-9-ylmethoxy)-ethyl ester, having unexpected stability to acid and base conditions, used for treating hepes infections; acylating acyclovir with 1-tert-butoxycarbonylamino-cyclopropanecarboxylic acid, the deprotecting the amine
12/02/2010WO2010138084A1 CRYSTAL STRUCTURE OF CAP-FREE HUMAN eIF4E
12/02/2010WO2010103547A3 Substituted fused pyrimidine compounds
12/02/2010US20100305096 Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
12/02/2010US20100304418 Compositions and Methods for Monitoring Flow Through Fluid Conducting and Containment Systems
12/01/2010EP1368342B3 Benzimidazole and pyridylimidazole derivatives as ligands for gaba receptors
12/01/2010CN101903389A Pharmaceutically acceptable salts of methyl (3-{ [[3-(6- amino- 2-butoxy-8-oxo-7, 8-dihydro-9h-purin-9-yl) propyl] (3- morpholin-4-ylpropyl) amino] methyl }phenyl) acetate and their use in therapy
12/01/2010CN101899063A Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one
12/01/2010CN101899045A 9-substituted-2-amino-6-guanidyl purine compounds as well as preparation method and application thereof
12/01/2010CN101899010A Quinazol derivative, preparation method and application thereof
11/2010
11/30/2010US7842693 For therapy of rheumatoid arthritis, multiple sclerosis, transplant rejection, dermnatitis, eczema, urticaria, vasculitis, inflammatory bowel disease, food allergy and encephalomyelitis
11/30/2010CA2144474C Substituted n-ethylglycine derivatives for preparing pna and pna/dna hybrids
11/25/2010US20100298564 Preparation of amorphous valganciclovir hydrochloride
11/25/2010US20100298354 Crystalline Form Of Abacavir That Is Essentially Free Of Solvent
11/25/2010US20100298319 Pyrimidine substituted purine derivatives
11/25/2010US20100297128 Gamma secretase modulators
11/24/2010EP1501829B1 Thiadiazoles or oxadiazoles and their use as inhibitors of jak protein kinase
11/24/2010CN101896484A Theobromine production process
11/24/2010CN101891741A New synthesis process of antiviral drug entecavir
11/23/2010US7838529 type II diabetes mellitus and obesity; dipeptidylpeptidase-IV (DPP-IV) inhibitor; 1-[2-(2-formylaminophenyl)-2-oxoethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-aminopiperidin-1-yl)xanthine (xanthine=3,7-dihydro-purine-2,6-dione)
11/23/2010US7838528 Substituted bicyclic 8-pyrrolidinoxanthines, methods for their production, pharmaceutical formulations and their use
11/23/2010US7838523 [5-(Pyridin-2-ylamino)-6-oxo-1,6-dihydro-pyridin-3-yl]-(3-amido)-benzene derivatives; anticarcinogenic, antiproliferative, antiallergen, and antiinflammatory agents; lymphoma, leukemia, autoimmune diseases; Bruton's tyrosine kinase inhibitors
11/23/2010US7838520 Inhibitors of histone deacetylase
11/23/2010CA2563022C Process for preparing 1,3-dioxolane derivatives
11/23/2010CA2342200C Use of certain drugs for treating nerve root injury
11/23/2010CA2223989C Prodrugs of pharmaceuticals with improved bioavailability
11/18/2010WO2010111626A3 Poly (adp-ribose) polymerase (parp) inhibitors
11/18/2010US20100292472 Prophylactic and therapeutic medicine for malaria
11/18/2010US20100292471 Peptide nucleic acid oligomers comprising universal bases,preparation methods thereof, and kits, devices and methods for the analysis, detection or modulation of nucleic acids using the same
11/18/2010US20100292455 MODIFIED iRNA AGENTS
11/18/2010US20100292255 Therapeutic Compounds and Their Use in Treating Diseases and Disorders
11/18/2010US20100290990 Method for preparing a marked purine derivative, said derivative and uses thereof
11/18/2010CA2760778A1 Heteroaryl compounds as pikk inhibitors
11/17/2010EP2251015A1 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
11/17/2010CN101889015A Pyrimidine substituted purine derivatives
11/16/2010US7834181 Small-molecule Hsp90 inhibitors
11/16/2010CA2409613C Methods and compositions for treating hepatitis c virus
11/11/2010WO2010129053A2 Egfr inhibitors and methods of treating disorders
11/11/2010WO2010108051A3 Inhibitors of diacylglycerol o-acyltransferase 1(dgat-1) and uses thereof
11/11/2010WO2010093436A3 Toll-like receptor modulators and treatment of diseases
11/11/2010WO2010074534A3 Novel intermediate and process for preparing entecavir using same
11/11/2010US20100286126 Organic Compounds
11/11/2010US20100286089 Process for the Preparation of Entecavir and Novel Intermediates Thereof Via Carbon-Silicon Oxidation
11/11/2010US20100284959 Sequence specific double-stranded dna/rna binding compounds and uses thereof
11/11/2010CA2760794A1 Egfr inhibitors and methods of treating disorders
11/10/2010EP2248813A1 Production method and production device for composition having high content of theobromine
11/10/2010EP1912991B1 Xanthine derivatives as selective hm74a agonists
1 ... 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 ... 120